Physician profile
Lucybeth Nieves Arriba
NPI 1386735827
$251,004.18
in general payments reported to CMS, 2019-2025
22 companies · $28K in 2025
The $28K reported for 2025 was more than what 95% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $32K · 2021: $32K · 2022: $44K · 2023: $37K · 2024: $28K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Travel and Lodging: $11K · Consulting Fee: $5,045 · Food and Beverage: $2,820 · Education: $64.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,525.00 |
| Travel and Lodging | $11,322.00 |
| Consulting Fee | $5,045.00 |
| Food and Beverage | $2,820.17 |
| Education | $64.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $134,806.95 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals Lp | $71,497.78 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Tesaro, INC. | $42,188.64 | 2019 | |
| Ethicon US, LLC | $1,746.53 | 2020-2025 | Harmonic, Stratafix, Megadyne |
| Merck Sharp & Dohme LLC | $155.85 | 2019-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $106.38 | 2023-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $78.99 | 2023-2025 | Darzalex, Tecvayli, Imbruvica |
| Eisai INC. | $65.81 | 2023 | |
| Novartis Pharmaceuticals Corporation | $47.33 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.74 | 2023-2024 | Iclusig, Alunbrig |
| Foundation Medicine, INC. | $38.02 | 2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Alexion Pharmaceuticals, INC. | $37.83 | 2023-2024 | Ultomiris |
| Pfizer INC. | $36.31 | 2022-2023 | |
| Incyte Corporation | $29.87 | 2023-2024 | Monjuvi, Pemazyre, Jakafi |
| Lilly USA, LLC | $23.42 | 2023 | Retevmo, Jaypirca, Verzenio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.46 | 2024 | Gazyva, Venclexta |
| Sobi, INC | $17.37 | 2024 | |
| Tempus Ai, INC | $16.68 | 2025 | Xt Cdx |
| Medtronic, INC. | $14.39 | 2024 | Truclear |
| Bayer Healthcare Pharmaceuticals INC. | $13.85 | 2025 | |
| Exelixis INC. | $12.80 | 2023 | Cabometyx |
| Clovis Oncology, INC. | $10.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucybeth Nieves Arriba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.